Literature DB >> 15673786

Stability of fluoroquinolone resistance in Streptococcus pneumoniae clinical isolates and laboratory-derived mutants.

Heather J Smith-Adam1, Kimberly A Nichol, Daryl J Hoban, George G Zhanel.   

Abstract

The stability of fluoroquinolone resistance in Streptococcus pneumoniae was evaluated in laboratory-derived mutants and clinical isolates. Isolates with various genotypes and phenotypes were subcultured for 20 days on antibiotic-free media and were monitored by E-tests to identify any alterations in resistance. Fluoroquinolone resistance mechanisms, whether efflux or chromosomally mediated, remained stable in both clinical and laboratory-derived mutants.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15673786      PMCID： PMC547370          DOI： 10.1128/AAC.49.2.846-848.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

2.  Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.

Authors:  I Morrissey; J George
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

3.  Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000.

Authors:  P L Ho; R W Yung; D N Tsang; T L Que; M Ho; W H Seto; T K Ng; W C Yam; W W Ng
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

4.  Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995.

Authors:  Angela B Brueggemann; Stacy L Coffman; Paul Rhomberg; Holly Huynh; Laurel Almer; Angela Nilius; Robert Flamm; Gary V Doern
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae.

Authors:  Laura J V Piddock; Maggie M Johnson; S Simjee; L Pumbwe
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

6.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada.

Authors:  George G Zhanel; Andrew Walkty; Kim Nichol; Heather Smith; Ayman Noreddin; Daryl J Hoban
Journal:  Diagn Microbiol Infect Dis       Date:  2003-01       Impact factor: 2.803

9.  Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

Authors:  George G Zhanel; Lorraine Palatnick; Kimberly A Nichol; Tracy Bellyou; Don E Low; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

10.  Molecular epidemiology of penicillin-resistant and ciprofloxacin-resistant Streptococcus pneumoniae in Canada.

Authors:  Kimberly A Nichol; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191
View more
  1 in total

Review 1.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.